Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.

Purpose To identify dynamic optical imaging features that associate with the degree of pathologic response in patients with breast cancer during neoadjuvant chemotherapy (NAC). Materials and Methods Of 40 patients with breast cancer who participated in a longitudinal study between June 2011 and March 2016, 34 completed the study. There were 13 patients who obtained a pathologic complete response (pCR) and 21 patients who did not obtain a pCR. Imaging data from six subjects were excluded from the study because either the patients dropped out of the study before it was finished or there was an instrumentation malfunction. Two weeks into the treatment regimen, three-dimensional images of both breasts during a breath hold were acquired by using dynamic diffuse optical tomography. Features from the breath-hold traces were used to distinguish between response groups. Receiver operating characteristic (ROC) curves and sensitivity analysis were used to determine the degree of association with 5-month treatment outcome. Results An ROC curve analysis showed that this method could identify patients with a pCR with a positive predictive value of 70.6% (12 of 17), a negative predictive value of 94.1% (16 of 17), a sensitivity of 92.3% (12 of 13), a specificity of 76.2% (16 of 21), and an area under the ROC curve of 0.85. Conclusion Several dynamic optical imaging features obtained within 2 weeks of NAC initiation were identified that showed statistically significant differences between patients with pCR and patients without pCR as determined 5 months after treatment initiation. If confirmed in a larger cohort prospective study, these dynamic imaging features may be used to predict treatment outcome as early as 2 weeks after treatment initiation. © RSNA, 2018 Online supplemental material is available for this article.

[1]  M. Untch,et al.  Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological. , 2011, Journal of the National Cancer Institute. Monographs.

[2]  A M Thompson,et al.  Neoadjuvant treatment of breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Jeremy C. Hebden,et al.  Optical tomography of breast cancer—monitoring response to primary medical therapy , 2009, Targeted Oncology.

[4]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[5]  Quing Zhu,et al.  Ultrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers , 2016, Ultrasonic imaging.

[6]  B. Pogue,et al.  In vivo quantitative imaging of normal and cancerous breast tissue using broadband diffuse optical tomography. , 2010, Medical physics.

[7]  L. Costaridou,et al.  Assessing heterogeneity of lesion enhancement kinetics in dynamic contrast-enhanced MRI for breast cancer diagnosis. , 2010, The British journal of radiology.

[8]  Brian W Pogue,et al.  Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer? , 2011, Radiology.

[9]  B. Pogue,et al.  Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. , 2009, Radiology.

[10]  M. Huang,et al.  Utilizing optical tomography with ultrasound localization to image heterogeneous hemoglobin distribution in large breast cancers. , 2005, Neoplasia.

[11]  Li-Yun Chang,et al.  Vascularity change and tumor response to neoadjuvant chemotherapy for advanced breast cancer. , 2008, Ultrasound in medicine & biology.

[12]  Quing Zhu,et al.  Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography. , 2013, Radiology.

[13]  Hany Soliman,et al.  Diffuse optical spectroscopy evaluation of treatment response in women with locally advanced breast cancer receiving neoadjuvant chemotherapy. , 2012, Translational oncology.

[14]  B. Tromberg,et al.  Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy , 2007, Proceedings of the National Academy of Sciences.

[15]  M. Huang,et al.  Benign versus malignant breast masses: optical differentiation with US-guided optical imaging reconstruction. , 2005, Radiology.

[16]  Quing Zhu,et al.  Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria , 2014, Breast Cancer Research.

[17]  M. Herranz,et al.  Optical Imaging in Breast Cancer Diagnosis: The Next Evolution , 2012, Journal of oncology.

[18]  David A Boas,et al.  Assessing the future of diffuse optical imaging technologies for breast cancer management. , 2008, Medical physics.

[19]  Regine Choe,et al.  Towards non-invasive characterization of breast cancer and cancer metabolism with diffuse optics. , 2013, PET clinics.

[20]  G. von Minckwitz,et al.  Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit? , 2013, Breast.

[21]  Carsten Denkert,et al.  Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial , 2013, PloS one.

[22]  Quing Zhu,et al.  Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. , 2008, Neoplasia.